Amgen Inc. (AMGN) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Thousand Oaks, CA, アメリカ. 現CEOは Robert A. Bradway.
AMGN を有する IPO日 1983-06-17, 28,000 名の正社員, に上場 NASDAQ Global Select, 時価総額 $189.19B.
Amgen Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics across key therapeutic areas including inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience. The company's extensive portfolio includes major brands such as Enbrel for rheumatoid arthritis and psoriasis, Neulasta for chemotherapy side effects, Prolia for osteoporosis, Repatha for cardiovascular risk reduction, and KYPROLIS for multiple myeloma, among many others. Amgen distributes its products through pharmaceutical wholesalers and direct-to-consumer channels to healthcare providers including physicians, hospitals, dialysis centers, and pharmacies worldwide. The company actively pursues strategic collaborations with leading pharmaceutical and biotechnology partners to advance its pipeline and expand treatment options across multiple disease areas. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen has established itself as a leader in the global biopharmaceutical industry.
